Key facts
- It has raised $10.1M; the latest was Early Stage VC ($10.1M) in Sep 2025.
- Notable investors include Investissement Quebec, Fonds de solidarite FTQ, CTI Life Sciences Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Oligon Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Oligon Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oligon Therapeutics
Developer of a next-generation RNAi therapeutic platform designed to reprogram disease-related cells with high precision. The company offers a modular self-delivering RNA drug architecture that integrates dual aptamer binders with dual silencers, enabling researchers and biotech developers to target any cell type, including immune and cancer cells, with unprecedented selectivity and potency.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2021
- Employees
- 4
- Website
- oligon.com/
- Ownership
- Privately Held (backing)
Oligon Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oligon Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oligon Therapeutics in its N-PORT filings yet. We sweep new filings monthly.